Study evaluates chidamide for patients with peripheral T-cell lymphoma | HIV tied to increased risk of cancer-specific mortality | Study evaluates discontinuation of bleomycin, vincristine in lymphoma regimen
June 26, 2015
AABB SmartBrief
News for the transfusion medicine and cellular therapy community

Top StorySponsored By
Study evaluates chidamide for patients with peripheral T-cell lymphoma
In a 79-patient Phase II study, chidamide was associated with an overall response rate of 28% among patients with relapsed or refractory peripheral T-cell lymphoma. Patients with angioimmunoblastic T-cell lymphoma had a higher response rate. The findings were published in the Annals of Oncology. (6/24)
Share: LinkedInTwitterFacebookGoogle+Email
Choose a centrifuge that gives reproducible performance.
For reliable results, ensure that your blood centrifuge compensates for setup variances. The Hettich ROTO SILENTA 630RS blood processing centrifuge features a powerful motor that delivers precise force regardless of varying load weights. Additionally, preset braking programs ensure the integrity of samples is maintained during end of run. Learn more.
Science & Health
HIV tied to increased risk of cancer-specific mortality
HIV-positive patients are at greater risk of cancer-specific mortality for several types of common cancers regardless of stage and treatment, according to a retrospective analysis of data involving 1,816,461 patients. The findings were published in the Journal of Clinical Oncology. 2 Minute Medicine (6/25)
Share: LinkedInTwitterFacebookGoogle+Email
Study evaluates discontinuation of bleomycin, vincristine in lymphoma regimen
A 3,309-patient study found that the discontinuation of bleomycin and vincristine from a seven-drug Hodgkin lymphoma regimen was not associated with significant differences in progression-free survival or overall survival. The findings were reported in the Journal of Clinical Oncology. (6/24)
Share: LinkedInTwitterFacebookGoogle+Email
Emerging Trends
Stem cells' effect on diabetic neuropathy studied in mice
Tests in mouse models of diabetic neuropathy found that injections of bone-marrow-derived mesenchymal stem cells were associated with blood vessel growth and nerve remyelination. The findings were reported in the journal Cell Transplantation. (U.K.) (6/25), Genetic Engineering & Biotechnology News (6/24)
Share: LinkedInTwitterFacebookGoogle+Email
Animal study assesses foam spray
A study in the journal Biomaterials Science and Engineering found that a foam spray made from chitosan reduced blood loss in pigs by 90%. The spray was developed using processed shells of crustaceans. United Press International (6/25)
Share: LinkedInTwitterFacebookGoogle+Email
Industry News & Practice
Trial data reported for hemophilia drug turoctocog alfa
Novo Nordisk announced at the International Society on Thrombosis and Haemostasis that a Phase III trial found that one or two infusions of its coagulant turoctocog alfa, or NovoEight, treated 90% of bleeding events among hemophilia A patients. Turoctocog alfa has been approved in the U.S. and Europe for the control and prevention of bleeding associated with hemophilia A. PharmaTimes (U.K.) (6/25), Reuters (6/24)
Share: LinkedInTwitterFacebookGoogle+Email
Late-stage data reported for acute myeloid leukemia drug
An ongoing open-label, late-stage trial found that Celator Pharmaceuticals' CPX-351 did not meet a primary endpoint of improved overall survival in the year following treatment. The rate of overall survival at one year was significantly improved for patients classified as being at poor risk using the European Prognostic Index. OncLive (6/25)
Bristol-Myers Squibb ceases antiviral discovery program
Bristol-Myers Squibb has decided to cancel a program that identifies new antiviral drug candidates, including its work on hepatitis B and HIV. The company said products that have reached market and candidates that have reached clinical development, such as the HIV attachment inhibitor BMS-663068 and hepatitis C drug daclatasvir, will not be affected. Reuters (6/25), PharmaTimes (U.K.) (6/25)
Share: LinkedInTwitterFacebookGoogle+Email
Government & Regulatory
European regulators approve Daiichi Sankyo's edoxaban
The European Commission approved Daiichi Sankyo's once-daily anticoagulant Lixiana, or edoxaban, for the prevention of stroke and systemic embolism in nonvalvular atrial fibrillation patients and for the treatment and prevention of deep vein thrombosis and pulmonary embolism. PharmaTimes (U.K.) (6/25)
Share: LinkedInTwitterFacebookGoogle+Email
Association News
Members encouraged to take advantage of mentoring program for young professionals
AABB encourages members to take part in the Professional Engagement Program's mentoring program, which pairs experienced professionals with members who have less than five years of experience in transfusion medicine, cellular therapies or patient blood management. Mentors, who have at least five years of experience in these fields, are asked to make one or two informal calls a month to the mentee with whom they are matched. Mentors and mentees will be matched based on job requirements, career goals and interests. To register or for more information, visit the AABB Volunteer Opportunities webpage or contact
Share: LinkedInTwitterFacebookGoogle+Email
powered by
Operations Coordinator, Blood Bank
Clincial Laboratory Scientist-Advanced
Clinical Laboratory Scientist - Reference Lab
Manufacturing/Hospital Services Manager
Reference Laboratory Supervisor
The moments of happiness we enjoy take us by surprise. It is not that we seize them, but that they seize us."
-- Ashley Montagu,
Share: LinkedInTwitterFacebookGoogle+Email
Learn more about AABB® ->Homepage | Join AABB | Conferences | Marketplace | AABB CareerLink
Subscriber Tools
Please contact one of our specialists for advertising opportunities, editorial inquiries, job placements, or any other questions.
Editor:  Tom Parks
Advertising:  Meryl Harold
  P: 202.407.7828

Mailing Address:
SmartBrief, Inc.®, 555 11th ST NW, Suite 600, Washington, DC 20004
© 1999-2015 SmartBrief, Inc.®
Privacy policy |  Legal Information